E Merck provides funds for VWR acquisition
This article was originally published in Clinica
In a string of deals last week, German company E Merck raised its stake in US-based VWR, which in turn used the funds to purchase Baxter International's industrial division. The result is a further strengthening of E Merck's interests in laboratory distribution and a concomitant lessening of Baxter's weighting in areas less profitable than its medical specialties business.
You may also be interested in...
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.